Protocol Ledger

NCT07881458 · Phase III · RECRUITING

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Interventional Phase III clinical trial protocol NCT07881458 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-16 Enrollment: 1,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07881458
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07881458
Protocol FieldVerified Registry Value
NCT IdentifierNCT07881458
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,000 participants (ESTIMATED)
Registered Start Date2026-10-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07881458
Hospital Research SiteLocationSite Profile
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI